Extended-spectrum β-lactamases in Gram Negative Bacteria.
Rawat D, Nair D. · 2010
Read Extended-spectrum β-lactamases in Gram Negative Bacteria. by Rawat D, Nair D. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2946684.txt.
Introduction
Rawat and Nair reviewed extended-spectrum beta-lactamases, bacterial enzymes that defeat many modern antibiotics, in a 2010 article. These plasmid-carried enzymes spread fast and complicate care in hospitals and the community alike.
The enzymes break down third-generation cephalosporins and a related drug, yet are blocked by clavulanic acid, a trait labs use to detect them. Strains carrying them often resist several other drug families too, narrowing treatment choices. Infections range from simple bladder infections to life-threatening sepsis. Carbapenem antibiotics remain the choice for serious cases, though resistance to them has begun to appear.
Catalog record
| CREATOR | Rawat D, Nair D. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Extended-spectrum β-lactamases in Gram Negative Bacteria By Deepti Rawat, Deepthi Nair Published in: Journal of Global Infectious Diseases DOI: 10.4103/0974-777X.68531 ABSTRACT Abstract Extended-spectrum β-lactamases (ESBLs) are a group of plasmid-mediated, diverse, complex and rapidly evolving enzymes that are posing a major therapeutic challenge today in the treatment of hospitalized and community-based patients. Infections due to ESBL producers range from uncomplicated urinary tract infections to life-threatening sepsis. Derived from the older TEM is derived from Temoniera, a patient from whom the strain was first isolated in Greece. β-lactamases, these enzymes share the ability to hydrolyze third-generation cephalosporins and aztreonam and yet are inhibited by clavulanic acid. In addition, ESBL-producing organisms exhibit co-resistance to many other classes of antibiotics, resulting in limitation of therapeutic option. Because of inoculum effect and substrate specificity, their detection is also a major challenge. At present, however, organizations such as the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) provide guidelines for the detection of ESBLs in Klebsiella pneumoniae, K. oxytoca, Escherichia coli and Proteus mirabilis. In common to all ESBL-detection methods is the general principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic-resistance mechanisms in the face of the introduction of new antimicrobial agents. Thus there is need for efficient infection-control practices for containment of outbreaks; and intervention strategies, e.g., antibiotic rotation to reduce further selection and spread of these increasingly resistant pathogens. Keywords: Extended-spectrum β-lactamases, Gram negative bacteria (GNB) and Antimicrobial resistance INTRODUCTION Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam but are inhibited by clavulanic acid. They represent the first example in which β-lactamase–mediated resistance to β-lactam antibiotics resulted from fundamental changes in the substrate spectra of the enzymes.[1] The total number of ESBLs now characterized exceeds 200. These are detailed on the authoritative website on the nomenclature of ESBLs hosted by George Jacoby and Karen Bush (http://www.lahey.org/studies/webt.htm). Published research on ESBLs has now originated from more than 30 different countries, reflecting the truly worldwide distribution of ESBL-producing organisms. Enterobacteriaceae, especially Klebsiella spp.-producing ESBLs such as SHV and TEM types, have been established since the 1980s as a major cause of hospital-acquired infections. However, during the late 1990s, several community-acquired pathogens that commonly cause urinary tract infections and diarrhea have also been found to be ESBL producers. These include Escherichia coli, Salmonella, Shigella and Vibrio cholerae.[2–4] ESBLs are often encoded by genes located on large plasmids, and these also carry genes for resistance to other antimicrobial agents such as aminoglycosides, trimethoprim, sulphonamides, tetracyclines and chloramphenicol.[5] Recent studies have demonstrated fluoroquinolone resistance mediated by co-transfer of the qnr determinant on ESBL-producing plasmids.[6,7] Thus, very broad antibiotic resistance extending to multiple antibiotic classes is now a frequent characteristic of ESBL-producing enterobacterial isolates. As a result, ESBL-producing organisms pose a major problem for clinical therapeutics. This review attempts to present a comprehensive picture on the basis of the currently available literature about this diverse, complex and rapidly evolving group of enzymes. RESISTANCE TO Β-LACTAMS β-Lactams are a group of antibiotics acting on the cell wall of a bacterial cell. These include the penicillins, cephalosporins, carbapenems and monobactems. These bind to and inhibit the carboxypeptidases and transpeptidases. These are the cell wall synthesizing enzymes, also called the penicillin-binding proteins, or PBPs, that catalyze the D-ala D-ala cross linkages of the peptidoglycan wall that surrounds the bacterium. As a result, there is weakening of the cell wall structure, leading to cell lysis. Resistance to β-lactams has probably arisen throughout bacterial history but has become a useful and therefore selected trait since the β-lactam antibiotics came into clinical use. These drugs exerted a Darwinian selection, killing susceptible bacteria and allowing the resistant ones to survive. Resistance to β-lactams may be inherent to a particular species, as seen in enterococci, which have inherently insensitive PBPs. Alternately, it may be acquired through spontaneous mutation or DNA transfer. Functionally, β-lactam resistance may be a result of the production of β-lactamases, impermeability, efflux and target modification. These modalities may occur singly or in different combinations. The most common causes of resistance in gram-positive cocci like pneumococci and MRSA are changes in the normal PBPs or acquisition of additional β-lactam–insensitive PBPs. However, in the gram-negative bacteria, resistance is mostly due to a combination of endogenous acquired β-lactamases, along with natural up-regulated impermeability and efflux.[8] DEFINITION OF EXTENDED-SPECTRUM Β-LACTAMASES There is no consensus on the precise definition of ESBLs. A commonly used working definition is that, ESBLs are β-lactamases capable of conferring bacterial resistance to the penicillins; first-, second- and third-generation cephalosporins; and aztreonam (but not the cephamycins or carbapenems) by hydrolysis of these antibiotics, and which are inhibited by β-lactamase inhibitors such as clavulanic acid.[2] The Ambler molecular classification and the Bush-Jacoby-Medeiros functional classification are the two most commonly used classification systems for β-lactamases.[9–11] Ambler scheme divides β-lactamases into four major classes (A to D). The basis of this classification scheme rests upon protein homology (amino acid similarity) and not phenotypic characteristics. In the Ambler classification scheme, β-lactamases of classes A, C and D are serine β-lactamases. In contrast, the class B enzymes are metallo-β-lactamases. With the exception of OXA-type enzymes (which are class D enzymes), the ESBLs are of molecular class A. The Bush-Jacoby-Medeiros classification scheme groups β-lactamases according to functional similarities (substrate and inhibitor profile). There are four main groups and multiple subgroups in this system. This classification scheme is of much more immediate relevance to the physician or microbiologist in a diagnostic laboratory because it considers β-lactamase and β-lactam substrates that are clinically relevant. In this classification, ESBLs belong to group 2be or group 2d (OXA-type), the latter sharing most of the fundamental properties of group 2be enzymes though differing in being inhibitor resistant.[10] The 2be designation shows that these enzymes are derived from group 2b β-lactamases (for example, TEM-1, TEM-2 and SHV-1); the ‘e ’ of 2be denotes that the β-lactamases have an extended spectrum. The ESBLs derived from TEM-1, TEM-2 or SHV-1 differ from their progenitors by as few as one amino acid. This results in a profound change in the enzymatic activity of the ESBLs, so that they can now hydrolyze the third-generation cephalosporins or aztreonam (hence the extension of spectrum compared to the parent enzymes). Inhibition by β-lactamase inhibitors such as clavulanic acid and inability to hydrolyze cephamycins differentiates the ESBLs from the AmpC-type β-lactamases (group 1), which have third-generation cephalosporins as their substrates but which are not inhibited by clavulanic acid. Selection of stably de-repressed mutants which hyperproduce the AmpC-type β-lactamases has been associated with clinical failure when third-generation cephalosporins are used to treat serious infections with organisms producing these enzymes.[12–14] In general, the fourth-generation cephalosporin, cefepime, is clinically useful against organisms producing AmpC-type β-lactamases[15] but may be less useful in treating ESBL-producing organisms.[16] Additionally, the metalloenzymes (group 3) produced by organisms such as Stenotrophomonas maltophilia can hydrolyze third-generation cephalosporins (and carbapenems) but are inhibited